Ikonisys
Business Services · Connecticut, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5 Science Park, New Haven, Connecticut, ...Phone Number
(203) 776-0791Website
www.ikonisys.comRevenue
<$5 MillionStock Symbol
ALIKOIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).Explore more
Ikonisys Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ikonisys your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Ikonisys is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Ikonisys
Ikonisys, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ikonisys has new funding data
Product Launch: Get notified when Ikonisys launches new products
Check if Ikonisys has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ikonisys recently announced quarterly report
Click to see if Ikonisys had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Ikonisys as Masked Content
Find more new buyers
Compare Similar Companies to Ikonisys
Compare insights from companies similar to Ikonisys, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$7.3M
11-50
Private
$19.1M
2009
JG
Jennifer GassmanRegional Director, Implementation & Clinical Outcomes
Company Profile Activity
Activity Insights
Ikonisys is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ikonisys is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ikonisys.
Ikonisys financials insights
Gather financial insights about Ikonisys, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Unspecified
$3.8M
2012
Unspecified
$1.4M
2021
Debt
$117K
2022
Debt
$6.3M
2023
Share Placement
$535K
2024
Share Placement
$208K
2025
Other Financing Round
$541K
Ikonisys Tech Stack
A closer look at the technologies used by Ikonisys
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Funding
Mergers & Acquisitions (M&A)
Funding
Funding
Ikonisys News & Media
Ikonisys: Hospitex Secures Major Public Tender for "Gaetano Martino" University Hospital in Messina
PARIS--(BUSINESS WIRE)--Regulatory News: Hospitex, the Italian leader in the production of medical devices and a subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), today announces that it has secured a public tender for the Azienda Ospedaliera Universitaria "Gaetano Martino" in Messina, Italy. The contract, valued at €668 thousand over three years, includes an option to extend it for two additional years, bringing the total potential value to €1.025 million. The tenderIkonisys finalized a capital increase through the offsetting of debt - Business Wire
Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fIkonisys Finalized the Acquisition of Hospitex with the Issuance of 2M New Shares to ETH Scientific
PARIS--(BUSINESS WIRE)--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the “Issuer”), today announces that it has completed the acquisition of Hospitex International Srl, with the issuance of 2 million new Ikonisys shares to ETH Scientific Srl, the former owner of Hospitex. As disclosed in November 2023, Ikonisys signed an agreement toIkonisys Completed a Capital Increase Through a Private Placement
PARIS--(BUSINESS WIRE)--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the “Issuer”), today announces that it has completed a capital increase of €200k, by way of a private placement. This operation is part of the ongoing series of recent capital increases aimed at strengthening the Company's financial stability and diversifying its sh
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ikonisys
Sign Up For FreeTo access detailed company insights
Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analy... Read More
